Talphera reports Q3 results and seeks to end Niyad study enrollment early
+1 new source since this summary was written
Talphera reported third-quarter 2026 results on November 12 and said it asked the FDA to consider ending NEPHRO CRRT enrollment on December 31, 2026, even if the planned 70-patient target is not reached. The company said the blinded study currently has more than 80% statistical power for its primary endpoint. Talphera also lifted its estimated peak U.S. CRRT sales for nafamostat to more than $200 million and reported $14.2 million of cash and investments at September 30, 2026.
Why it matters
The FDA has not yet approved Talphera’s proposed enrollment approach, so the timing and eventual evidence package for a potential PMA filing remain dependent on agency feedback. Talphera said its cash, together with two conditional financing tranches totaling approximately $16 million, should fund operations through at least a potential Niyad PMA approval expected in 2027.
Key facts
- 1Talphera requested FDA feedback on using the patients enrolled by December 31, 2026 as the final NEPHRO CRRT sample, rather than necessarily completing the planned 70 patients. prnewswire.com
- 2The company said the study has enrolled more than 75% of its planned patients and currently has over 80% power for the primary endpoint. sec.gov
- 3Talphera reported third-quarter net loss attributable to common shareholders of $4.0 million, or $0.05 per basic and diluted share. prnewswire.com
- 4Combined R&D and SG&A costs excluding non-cash stock-based compensation were $3.8 million in the third quarter of 2026, compared with $3.3 million in the third quarter of 2025. finance.yahoo.com
- 5Two conditional financing tranches were described as providing approximately $16 million of potential additional capital if their conditions are satisfied. finance.yahoo.com
- 6The company raised its estimated peak annual U.S. sales for nafamostat in CRRT to more than $200 million. finance.yahoo.com
Open questions
- The FDA’s response to Talphera’s request and the final number of enrolled patients are not yet known.
- The approximately $16 million in financing is conditional and may not be received unless the stated conditions are met.
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.